Association between EGF +61 G/A and glioma risk in a Chinese population

BMC Cancer

Table 3 Analysis of association between EGF+61 polymorphism and risk of glioma

	Case(%) N = 672	Control(%) N = 693	Crude P-value	Crude OR(95%CI)	Adjusted P*-value	Adjusted OR*(95%CI)	Adjusted P**-value	Adjusted OR**(95%CI)
Genotype
GG	298(44.34)	366(52.81)		1(Reference)		1(Reference)		1(Reference)
GA	305(45.39)	276(39.83)	0.007	1.36(1.09-1.70)	0.005	1.38(1.10-1.73)	0.001	1.48(1.17-1.87)
AA	69(10.27)	51(7.36)	0.011	1.66(1.12-2.46)	0.012	1.660(1.12-2.46)	0.005	1.81(1.20-2.72)
Allele#
G	901(67.04)	1008(72.73)		1(Reference)
A	443(32.96)	378(27.27)	0.001	1.31(1.11-1.55)
Dominant
GG	298(44.34)	366(52.81)		1(Reference)		1(Reference)		1(Reference)
GA+AA	374(55.66)	327(47.19)	0.002	1.41(1.14-1.74)	0.001	1.42(1.15-1.76)	0.0002	1.53(1.22-1.91)
Recessive
GG+GA	603(89.73)	642(92.64)		1(Reference)		1(Reference)		1(Reference)
AA	69(10.27)	51(7.36)	0.059	1.44(0.99-2.10)	0.066	1.43(0.98-2.09)	0.043	1.50(1.01-2.22)
Additive
GG	298(44.34)	366(52.81)	0.001	1.32(1.12-1.56)	0.001	1.33(1.12-1.57)	0.0002	1.40(1.17-1.66)
GA	305(45.39)	276(39.83)
AA	69(10.27)	51(7.36)

ISSN: 1471-2407